Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | MGLL | Q99685 | 1/20 | 0.32 |
| ▸ | LIPE | Q05469 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.30 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.30 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.30 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.30 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.30 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6903141 | 1.00 | KDM4E (0.42) | KDM4EGAAHPGDHRH3ALDH1A1 | |
| SCHEMBL681878 | 1.00 | KDM4E (0.42) | KDM4EGAAHPGDHRH3ALDH1A1 | |
| SCHEMBL16285870 | 0.98 | KDM4E (0.41) | KDM4EGAAHPGDHRH3ALDH1A1 | |
| SCHEMBL1117927 | 0.98 | KDM4E (0.41) | KDM4EGAAHPGDHRH3ALDH1A1 | |
| SCHEMBL21363734 | 0.98 | KDM4E (0.41) | KDM4EGAAHPGDHRH3ALDH1A1 | |
| SCHEMBL21398619 | 0.98 | KDM4E (0.41) | KDM4EGAAHPGDHRH3ALDH1A1 | |
| SCHEMBL19750189 | 0.98 | KDM4E (0.41) | KDM4EGAAHPGDHRH3ALDH1A1 | |
| SCHEMBL9963376 | 0.92 | — | — | |
| SCHEMBL681681 | 0.92 | — | — | |
| SCHEMBL17108529 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240217952-A1 | TREATMENT OF GRAFT-VERSUS-HOST DISEASE WITH INHIBITORS OF BET FAMILY BDII BROMODOMAIN | POSEIDON INNOVATION 1, INC. | 2024-07-04 | — | — | US | disclosed |
| US-11773102-B2 | Heterocyclic compounds as PI3K-γ inhibitors | INCYTE CORPORATION (US) | 2023-10-03 | — | — | US | disclosed |
| US-20230303512-A1 | MODULATORS OF MYB-MEDIATED TRANSCRIPTION AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230037448-A1 | FLUORINATED QUINOLINE AND QUINOXALINE DERIVATIVES AS DIHYDROOROTATE DEHYDROGENASE (DHODH) INHIBITORS FOR THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISEASES | NOVIRA THERAPEUTICS, LLC | 2023-02-09 | — | — | US | disclosed |
| US-20230013585-A1 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS | GILEAD SCIENCES, INC. | 2023-01-19 | — | — | US | disclosed |
| US-20220213091-A1 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS | GILEAD SCIENCES, INC. | 2022-07-07 | — | — | US | disclosed |
| US-11203591-B2 | Substituted 6-azabenzimidazole compounds | GILEAD SCIENCES, INC. (US) | 2021-12-21 | — | — | US | disclosed |
| US-11091491-B2 | Heterocyclic compounds as PI3K-y inhibitors | INCYTE CORPORATION (US) | 2021-08-17 | — | — | US | disclosed |
| US-20210221804-A1 | 6-AMINOPYRIDIN-3-YL THIAZOLES AS MODULATORS OF RORyT | JANSSEN PHARMACEUTICA NV (BE) | 2021-07-22 | — | — | US | disclosed |
| US-20200031837-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2020-01-30 | — | — | US | disclosed |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
| US-20170313691-A1 | 6-AMINOPYRIDIN-3-YL THIAZOLES AS MODULATORS OF RORyT | JANSSEN PHARMACEUTICA NV (BE) | 2017-11-02 | — | — | US | disclosed |
| US-20170196862-A2 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-07-13 | — | — | US | disclosed |
| US-9663533-B2 | Thieno[3,2-C]pyridin-4(5H)-ones as BET inhibitors | GLAXOSMITHKLINE LLC (US) | 2017-05-30 | — | — | US | disclosed |
| WO-2017079519-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-GAMMA INHIBITORS | INCYTE CORPORATION (US) | 2017-05-11 | — | — | WO | disclosed |
| US-20170129899-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2017-05-11 | — | — | US | disclosed |
| US-20170050966-A1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | MERCK & CO., INC. | 2017-02-23 | — | — | US | disclosed |
| US-20170050966-A1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | MERCK & CO., INC. | 2017-02-23 | — | — | US | disclosed |
| US-20160297832-A1 | THIENO[3,2-C]PYRIDIN-4(5H)-ONES AS BET INHIBITORS | GLAXOSMITHKLINE LLC | 2016-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11773102-B2 | Heterocyclic compounds as PI3K-γ inhibitors | PIK3CD, PIK3CG, PIK3R5 | KDM4E 3824/4885GAA 185/4885HPGD 1135/4885 |
| US-20160297832-A1 | THIENO[3,2-C]PYRIDIN-4(5H)-ONES AS BET INHIBITORS | BRD4, BET1, BRD3 | KDM4E 226/4885GAA 1450/4885HPGD 533/4885 |
| US-20170050966-A1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | TRPA1, TRPV1, TRPV2 | KDM4E 4860/4885GAA 3460/4885HPGD 1674/4885 |
| US-11091491-B2 | Heterocyclic compounds as PI3K-y inhibitors | PIK3R5, PIK3CA, PIK3CD | KDM4E 2567/4885GAA 221/4885HPGD 1736/4885 |
| US-20230303512-A1 | MODULATORS OF MYB-MEDIATED TRANSCRIPTION AND USES THEREOF | MYB, MYBBP1A, MYCBP | KDM4E 315/4885GAA 3712/4885HPGD 3505/4885 |
| US-20240217952-A1 | TREATMENT OF GRAFT-VERSUS-HOST DISEASE WITH INHIBITORS OF BET FAMILY BDII BROMODOMAIN | BRDT, BET1, BRD4 | KDM4E 674/4885GAA 2403/4885HPGD 1327/4885 |
| US-11203591-B2 | Substituted 6-azabenzimidazole compounds | CDK6, HIPK1, DCK | KDM4E 1027/4885GAA 1464/4885HPGD 539/4885 |
| US-20220213091-A1 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS | CDK6, HIPK1, DCK | KDM4E 1027/4885GAA 1464/4885HPGD 539/4885 |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | SMARCC1, SMARCC2, SMARCA4 | KDM4E 1623/4885GAA 1161/4885HPGD 3999/4885 |
| US-20170313691-A1 | 6-AMINOPYRIDIN-3-YL THIAZOLES AS MODULATORS OF RORyT | RORC, RORA, RORB | KDM4E 2096/4885GAA 4027/4885HPGD 3699/4885 |
| US-20200031837-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS | PIK3R5, PIK3CA, PIK3CD | KDM4E 2567/4885GAA 221/4885HPGD 1736/4885 |
| US-20170129899-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS | PIK3R5, PIK3CA, PIK3CD | KDM4E 2567/4885GAA 221/4885HPGD 1736/4885 |
| US-20210221804-A1 | 6-AMINOPYRIDIN-3-YL THIAZOLES AS MODULATORS OF RORyT | RORC, RORA, RORB | KDM4E 2096/4885GAA 4027/4885HPGD 3699/4885 |
| US-20170196862-A2 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | KDM4E 2973/4885GAA 2007/4885HPGD 1850/4885 |
| US-20230037448-A1 | FLUORINATED QUINOLINE AND QUINOXALINE DERIVATIVES AS DIHYDROOROTATE DEHYDROGENASE (DHODH) INHIBITORS FOR THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISEASES | DHODH, NQO2, DPYD | KDM4E 1820/4885GAA 1005/4885HPGD 119/4885 |
| US-20230013585-A1 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS | CDK6, HIPK1, DCK | KDM4E 1027/4885GAA 1464/4885HPGD 539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.